RNS Number : 3344X
Minster Pharmaceuticals PLC
24 June 2008
For Immediate Release 24 June 2008
MINSTER PHARMACEUTICALS PLC
("Minster" or "the Company")
Annual General Meeting
Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in
neurological and psychiatric disorders, will hold
its Annual General Meeting this morning, at which John Russell, the Company's Chairman, will
make the following comments:
"I am pleased to report that the current year has started well. Our 500-patient Phase IIb
study of tonabersat in the prevention of
migraine is now fully enrolled and we look forward to the results of the study in the early
part of 2009. These results will provide the
impetus for increased momentum in discussions with potential licensing partners for the
commercialisation of the compound.
"The prevention of migraine is one of the fastest growing segments of the pharmaceutical
market, which, combined with our clinical work
to date, gives us confidence that Minster is ideally positioned to become a significant force
in the migraine market.
"We also continue to progress the earlier stage opportunities in our pipeline including
sabcomeline in schizophrenia and tonabersat in
the further indications of neuropathic pain and epilepsy."
For further information:
Minster Pharmaceuticals plc Tel: +44 (0) 1799 506623
Paul Sharpe, Chief Executive Officer
Robert Aubrey, Chief Financial Officer
Buchanan Communications Tel: +44 (0) 20 7466 5000
Mark Court
Rebecca Skye Dietrich
Catherine Breen
Nomura Code Securities Limited Tel: +44 (0) 20 7776 1200
Richard Potts
Gerard Harper
Notes for editors:
About Minster Pharmaceuticals plc
Minster Pharmaceuticals is a drug development company focussed on neurological and
psychiatric disorders. Its principal pipeline assets
are tonabersat, under development in the preventive treatment of migraine, and sabcomeline in
schizophrenia. Worldwide rights to both
compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive
safety tolerance data as a result of investment by
GSK.
Tonabersat is the leading compound in an exciting new class of selective drugs designated
as neuronal gap junction blockers and offers
the potential to prevent the onset of migraine as a preferred alternative to acute treatment.Sabcomeline, a muscarinic partial agonist, has
potential in the treatment of chronic schizophrenia.
Minster's near-term focus is on the development and commercialisation of its current
pipeline. Its medium term strategy is to leverage
the anticipated cashflows from the current pipeline by in-licensing further compounds with the
ultimate objective of creating a substantial
and highly efficient drug development enterprise focussed on the central nervous system.
Minster joined the AIM market in February 2005 and trades under the symbol MPM. For
further information please visit
www.minsterpharma.com .
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFKNKNPBKDQAB
|